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Cachexia is a multifactorial syndrome that includes muscle
wasting and inﬂammation, and that is associated with chronic
underlying diseases, such as cancer, chronic heart failure and
chronic kidney disease. Since gut microbes inﬂuence host immu-
nity and metabolism, we hypothesized a few years ago that the gut
microbiota could be a potential therapeutic target to tackle cancer-
related cachexia. In this review, we present evidence from animal
and human studies suggesting that the gut microbiota and its
crosstalk with the intestine might constitute unexpected targets in
the therapeutic management of cancer and related cachexia.
Finally, we discuss future research directions and hypotheses to
progress in this new promising ﬁeld, i.e. the role of the gut
microbiota in cancer cachexia.
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Cachexia is deﬁned as amultifactorial syndrome characterized by an ongoing loss of skeletal muscle
mass (with or without fat mass loss), that cannot be fully reversed by conventional nutritional support
and leads to progressive functional impairment [1]. This metabolic syndrome has been reported in
patients with cancer, chronic heart failure (CHF), chronic kidney disease (CKD), chronic obstructive
pulmonary disease and chronic sepsis [2]. Its prevalence ranges from 5 to 15% in end-stage CHF to
50e80% in advanced cancer [3]. In 2011, a panel of experts proposed to use the following criteria to
diagnose cachexia: a weight loss greater than 5%, a weight loss greater than 2% in individuals already
showing depletion according to current bodyweight and height (body mass index <20 kg/m2), or
skeletal muscle mass (sarcopenia) [1]. Combined weight loss and cachexia reduce tolerance to cancer
treatment as well as the likelihood of response, and they both independently predict poor outcome [4].
It has been estimated that cancer-related cachexia could account for up to 20% of cancer deaths [5]. In
addition to reducing length of life, cancer cachexia decreases the quality of life [6] and constitutes a not
inconsiderable economical and health burden: the annual prevalence of cachexia in US community
hospitals was recently estimated at over 160,000 cases [3].
Cachexia is a multifactorial syndrome resulting from the interaction of several pathological pro-
cesses. Inﬂammation andmetabolites generated directly by the tumour - or released by the body due to
the presence of the tumour - alter host metabolism, leading to muscle atrophy, fat mass loss and in
some cases insulin resistance. Reduced food intake and physical activity further contribute to the
cachectic phenotype (Fig. 1) (for review on the aetiology of cachexia, see [2,5,7]).
Cachexia remains an often-neglected medical issue for which a clear therapeutic strategy is lacking.
Amultimodal approach is currently considered the best option to tackle cancer cachexia. This approach
would combine nutritional support with anti-inﬂammatory/anti-atrophy drugs or nutrients and
physical activity [7]. Several drug candidates are now under consideration to treat cachexia and
associated muscle wasting, such as anamorelin (an oral ghrelin-receptor agonist with appetite-Fig. 1. Components of the cachexia syndrome. Diagram inspired from the hallmarks of cancer, Hanahan and Weinberg [53].
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modulator) [8]. In addition to adequate nutritional support (in terms of caloric intake), several nutri-
tional agents have also been proposed to tackle cancer cachexia, such as n-3 polyunsaturated fatty
acids, leucine and microbiota-targeted interventions [8e13]. So far clear evidence of their efﬁcacy
remains limited. Most nutritional approaches have only shown beneﬁts in animal models. N-3 poly-
unsaturated fatty acids have displayed some promising results in clinical studies. Eicosapentaenoic
acid, N-3 polyunsaturated fatty acids or ﬁsh oil conferred beneﬁts in terms of energy and protein
intake, weight maintenance, body composition, fatigue, loss of appetite, quality of life and neuropathy.
However, these results would need to be conﬁrmed by independent large-scale trials before recom-
mendations to cancer patients with cachexia could be made [9,11,14]. To summarize, nutritional care is
now deemed as an essential component of the multimodal therapy for cancer cachexia, but the type of
nutritional care remains to be deﬁned and tested in large clinical settings [15].
In this review, we discuss the therapeutic potential of microbiota-targeted nutritional approaches to
treat cancer-related cachexia. We speculate on the pathways by which cancer could inﬂuence the
composition of the gut microbiota and review experimental evidence supporting a therapeutic role for
the gut microbiota in cancer cachexia. Future directions and working hypotheses are also presented.
2. How cancer and cachexia affect the gut microbiota
The trillions of microbes that reside in the gastrointestinal tract of mammals (i.e., the gut micro-
biota) are now considered a fully-ﬂedged component of our body. The gut microbiota plays a critical
role in biological processes such as nutrient utilization, resistance against infections, maturation of the
immune system, and host metabolism [16,17]. Research provided clear evidence that the gut micro-
biota maintains a symbiotic relationship with its host. Pending the provision of adequate substrates,
gut microbes can generate metabolites that will inﬂuence local and/or systemic host physiology, such
as short-chain fatty acids, organic acids, branched-chain fatty acids, bile acid derivatives, and vitamins.
Reciprocally, the host immune system and the gut barrier function afford protection against microbes
and shape the gut microbiota [17,18].
Recent studies suggest that the composition of the gut microbiota is affected by the presence of
tumour cells (even when implanted outside the gut) and the development of cancer-related cachexia.
We have recently highlighted a commonmicrobial signature for twomouse models of cancer cachexia,
the C26 model and the BaF model. The C26 model relies on a subcutaneous injection of colon carci-
noma cells whereas the BaFmodel mimics an acute leukaemia [19]. In bothmodels, Enterobacteriaceae
and Parabacteroides goldsteinii levels were increased in the caecal content of cancer-bearing mice
compared to control littermates, whereas Lactobacillus levels were decreased. Along those lines, Lin
and colleagues reported that subcutaneous implantation of colon cancer cells in rats disrupted the
intestinal microbiota, with the tumour-bearing state alone inducing greater changes than chemo-
therapy [20]. In their model, tumour implantation was associated with a one-log increase in faecal
levels of Enterobacteriaceae and Clostridium clusters I and XI. However the presence of cachexia in
these rats was not investigated by the authors. In humans, only a few clinical trials focussed on the gut
microbiota composition before any chemotherapy and antibiotic administration. In a pilot study,
Goedert and colleagues showed that postmenopausal women with breast cancer exhibit an altered
composition and low diversity of their gut microbiota [21]. To our knowledge, no studies have been
performed so far to investigate the relationship between cancer cachexia and the composition and/or
the function of the gut microbiota in cancer patients before any therapeutic intervention.
By which mechanisms the presence of tumour alters the gut microbiota composition remains to be
unravelled, and several scenarios could be envisioned. First, inﬂammation due to cancer development
could alter gut permeability, antimicrobial defence and Paneth cell function, leading to dysbiosis.
Secondly, we could envision that tumour-generated inﬂammation directly drives the dysbiosis. Indeed,
enteric inﬂammation resulting from various triggering factors alters microbial ecology and leads to
overgrowth of Enterobacteriaceae. The authors suggested that inﬂammation changes the intestinal
microbiota, and thereby supports colonization by aerotolerant bacteria [22]. Alternatively, it has been
reported that host-derived nitrate, generated as a by-product of the inﬂammatory response, directly
favours the growth of Escherichia coli in the gut [23]. A third scenario is based on microbial
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inﬂuence the host. Stress-related hormones, such as norepinephrine and epinephrine, can directly
interact with some bacteria (including ones from the Enterobacteriaceae family), thereby affecting
their growth and virulence [24]. Such scenarios could be envisioned in the context of cancer with
cachexia and may explain how the presence of a tumour can impact gut microbial ecology.
3. The rational to target the gut microbiota in cancer and cachexia
The interaction between host and gut microbiota in case of cancer is drawing more and more
attention. Gut microbiota inﬂuences tumour cell growth in gastro-intestinal cancers but also in cancers
occurring outside the gut (for review see [25e27]). One of the strongest evidence came from the
observation that cancer progression is reduced in germ-free or antibiotics-treated rodents [25]. Beside
a direct impact on cancer progression, gut microbes can modulate the efﬁciency of chemotherapy. For
instance, Viaud and colleagues brought evidence that anticancer immunity can be triggered by
cyclophosphamide through the intervention of the intestinal microbiota [28]. Altogether, these data
suggest that the gut microbiota can inﬂuence cancer progression and therapy.
The gut microbiota affects host metabolism and immunity [29], two key components in the
physiopathology of cachexia. Therefore, it is possible that the gut microbiota contributes to the aeti-
ology of cachexia. One of the mechanisms by which the gut microbiota may inﬂuence cancer cachexia
could involve alterations of the gut barrier function. Indeed, the gut barrier function is essential to limit
the translocation of bacterial compounds that can activate inﬂammatory and immune responses in
peripheral organs such as the liver and muscle. An example of such interplay is the LPS/TLR4/muscle
wasting pathway. Doyle and colleagues demonstrated that lipopolysaccharides (LPS), which are pro-
inﬂammatory compounds of bacterial origin, induce muscle catabolism through the toll-like recep-
tor (TLR) 4 [30]. If LPS is increased in the serum of cancer patients with cachexia is currently unknown.
We have recently shown that the gut barrier function is altered in a mouse model of leukaemia with
cachexia and that these alterations correlate with several bacterial taxa [19]. In accordance with our
ﬁndings, Puppa et al. showed an increased gut permeability in the ApcMin/þ mouse model of colon
cancer cachexia [31]. A pilot study performed in leukaemic patients reported a trend toward a higher
gut permeability in acute leukaemic patients prior to chemotherapy compared to healthy controls [32].
Along those lines, Jiang and colleagues found increased gut permeability and a higher probability of
bacterial translocation (deﬁned as presence of bacterial DNA in the portal serum) in cachectic versus
non cachectic patients with advanced gastric cancer [33]. Bacterial translocation was associated with
altered expression of the tight junction components Zonula Occludens 1, Occludin and Claudin-2 in the
colonic mucosa [33].
Altogether these observations support our current hypothesis, namely the inﬂammation due to
cancer development will alter the gut permeability, antimicrobial defences and Paneth cell function,
leading to dysbiosis. Thereafter, the altered intestinal homeostasis, microbial dysbiosis and cancer
would interact in a vicious cycle where cancer-induced alterations of intestinal homeostasis foster the
growth of detrimental bacteria, which further increase inﬂammation and cachexia through the
translocation of pro-inﬂammatory bacterial compounds (Fig. 2). Clearly, further studies devoted to
explore this hypothesis are needed and other hypotheses linking muscle wasting and gut microbiota
could be envisioned (for review see [34]).
All together, these studies provide a rational to target the gut microbiota in order to tackle cancer
and related cachexia.
4. Gut microbiota-targeted nutritional interventions for cancer cachexia
The therapeutic potential of the gut microbiota is currently exploited mainly through the use of
prebiotics, probiotics and faecal microbiota transplantation. We have recently proposed to deﬁne a
prebiotic as a non-digestible compound that, through its metabolization bymicroorganisms in the gut,
modulates the composition and/or activity of the gut microbes, thus conferring a beneﬁcial physio-
logical effect on the host [35]. Probiotics are deﬁned as live microorganisms which when administered
in adequate amounts confer a health beneﬁt on the host [36]. Faecal microbiota transplantation
Fig. 2. How the gut microbiota and the gut barrier function contribute to cancer cachexia: our current hypothesis.
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a nutritional intervention and will not be discussed here.
4.1. Experimental evidence for gut microbiota-targeted nutritional interventions
In the context of cancer cachexia, the therapeutic potential of the gut microbiota has been barely
explored so far. In a ﬁrst article, we showed that administration of a mixture of Lactobacillus reuteri
100-23 and Lactobacillus gasseri 311476 to leukaemic mice with cachexia restored the levels of these
bacteria in the caecum, reduced inﬂammation in the plasma and partially counteracted the induction
of atrophy markers in muscle [37]. We also showed a few years later that administration of a prebiotic
candidate, pectic oligosaccharides (POS), to leukaemic mice was able to alleviate the cachectic
phenotype, by delaying anorexia and sparing fat mass. In this context, we pointed out Bacteroides dorei
as a bacterium that was enriched by the consumption of POS. The relative abundance of Bacteroides
dorei was increased from 1% to 23% in cancer mice upon POS consumption [38]. The impact of this
bacterial species on host metabolism is currently unclear and would deserve further investigation.
We also investigated the impact of a selected complementary synbiotic approach in this mouse
model of leukaemia and cachexia. Complementary synbiotics are a mixture of prebiotics and probiotics
whereby the probiotic is chosen based on speciﬁc desired beneﬁcial effects on the host, and the pre-
biotic is independently chosen to selectively increase concentrations of beneﬁcial microbial compo-
nents [39]. The synbiotic mixture was designed based on a microbial signature we identiﬁed for cancer
cachexia. Indeed, when comparing two mouse models of cancer cachexia, we identiﬁed a common
microbial signature characterized by decreased lactobacilli levels and increased Enterobacteriaceae
levels. We therefore selected a prebiotic (short-chain inulin-type fructans) and a probiotic (L. reuteri
100-23) that could target some of the microbial alterations found in these cachectic mice. Adminis-
tration of the synbiotic restored lactobacilli levels and partially counteracted the increase in Enter-
obacteriaceae levels. This approach also reducedmuscle atrophy and leukaemic cell proliferation in the
liver. Furthermore, it prolonged survival and attenuated morbidity [19]. Several mechanisms may be
involved in the beneﬁts provided by this synbiotic approach. First, we observed that the gut barrier
function of these mice was deeply altered, with reduced expression of antimicrobial proteins, tight
junction proteins and immune markers. Because the synbiotic approach restored the intestinal ho-
meostasis [19], we propose that synbiotics could improve the phenotype through a modulation of the
gut barrier function. Deciphering the role of the gut permeability in the progression of cancer cachexia
is clearly one of the goals of the future studies. A second mechanism that may explain the beneﬁts
conferred by the administration of the synbiotics is the production of short-chain fatty acids, and
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increased propionate levels in the portal serum, a metabolite able to reduce the proliferation of leu-
kaemic cells [40]. Therefore, production of propionate by the synbiotic treatment may be one of the
mechanisms leading to a decreased accumulation of cancer cells in the liver. Finally, we cannot exclude
that speciﬁc bacteria, which levels are promoted by the synbiotic approach, exert immunomodulatory
effects on the host and thereby, impact cancer cachexia. Sequencing of the microbiome revealed that
the synbiotic approach increased the relative abundance of segmented ﬁlamentous bacteria and
Clostridium cluster XVIII [19]. Both bacterial taxa are known for their immunomodulatory properties.
Based on these observations, we propose that the beneﬁcial properties of this selected synbiotic
approach most likely rely on multiple mechanisms working together to improve host phenotype and
alleviate cancer cachexia.4.2. Can these experimental observations be translated to patients?
To our knowledge, no study has reported the impact of prebiotics or probiotics in cancer-related
cachexia so far. As discussed below, several interrelated factors would need to be taken into account
in the design of such study, including the safety proﬁle of the nutritional intervention, the integrity of
the gut barrier of the patients, and the type of chemotherapy.
The safety of a probiotic approach in cancer patients remains a matter of debate [41]. In 2008,
Besselink and colleagues reported an increased risk of mortality associatedwith the administration of a
mixture of probiotic candidates in patients with predicted severe acute pancreatitis [42]. After the
publication, several concerns were raised about the design of the study, and in particular the pretesting
conditions, dosages, way of administration and differences between groups on the day of random-
isation [43e45]. Anyway, this study points out the fact that probiotics should not be administrated if
the integrity of the gastro-intestinal tract is severely compromised, which might be the case under
chemotherapy or in cancer patients. A panel of experts analysed 57 studies to determine if adminis-
tration of probiotics to immune compromised patients is safe. The probiotic strains evaluated in the
meta-analysis were considered safe for the reported dosage and duration of administration. The au-
thors pointed out ﬂaws in precise reporting and classiﬁcation of adverse events in most studies and the
fact that generalisation is limited by the variation in probiotic strains, dosages, administration regimes,
study populations and reported outcomes [46].
In this context, prebiotics might be considered as a safer approach, favouring the growth of bacteria
already present in the gastrointestinal tract. Prebiotics have been proposed as nutritional strategy to
tackle chemotherapy-induced gut damages [47]. Further studies should determine if this approach
could also confer beneﬁts in term of cachexia.
5. Gut microbiota in other pro-cachectic diseases
A role for themicrobiota and/or microbial dysbiosis has been reported in other chronic diseases that
exhibit cachexia, such as chronic heart failure (CHF) and chronic kidney disease (CKD).
Several years ago, Sandek and colleagues proposed the gut and its associated microbes as targets for
therapeutic intervention in patients with CHF [48]. Among others, they reported intestinal epithelial
dysfunction and increased systemic levels of lipopolysaccharides in decompensated CHF [49]. Their
work also highlighted a reduced intestinal blood ﬂow in patients with CHF, especially for the patient
with cachexia [50].
A role for the gut microbiota and the gut barrier function in CKD has also been recently suggested. It
has been proposed that, due to the disruption of gut barrier function in CKD, endotoxin and bacterial
metabolites translocate to the systemic circulation and contribute to uremic toxicity, inﬂammation and
progression of CKD [51]. In accordance with this hypothesis, administration of prebiotics (gal-
actooligosaccharides) attenuated renal injury in nephrectomised rats, probably by decreasing the
production of indole in the caecum [52].
The mechanisms underlying cachexia in these pathological contexts remain unclear and are likely
multifactorial. We currently do not know if the cachectic phenotype associated with these diseases is
Fig. 3. A proposition to consider the gut as a fully-ﬂedged component of the cachexia syndrome.
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intervention. These questions would for sure deserve further investigation.
6. Conclusions
The treatment of cancer cachexia is multimodal with nutritional support and metabolism modu-
lation being essential components of the best supportive care for oncology patients. Nutritional ap-
proaches can provide beneﬁts to cancer cachectic patients through several aspects, by maintaining a
sufﬁcient energy intake, by modulating inﬂammation and as we proposed here, potentially by
impacting the gut microbiota and the gut barrier function (Fig. 3). We believe that the causal and
therapeutic roles of the gut microbiota in cancer cachexia deserve further investigation. So far, evi-
dence for a role for the gut microbiota in cachectic features relies mainly on experimental models.
Therefore, future studies aiming at investigating the link between gut microbiota and host metabolism
in cancer patients will be of critical importance. In parallel, mechanistic studies in experimental models
could lead to an optimization of the nutritional strategies and the discovery of new molecular thera-
peutic targets to tackle cancer cachexia.
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